

**NLM Citation:** Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Finerenone. [Updated 2021 Oct 18]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



#### **Finerenone**

Revised: October 18, 2021.

CASRN: 1050477-31-0

# **Drug Levels and Effects**

### **Summary of Use during Lactation**

No information is available on the use of finerenone during breastfeeding. Finerenone is 92% bound to plasma proteins, so amounts in milk are likely to be low. However, the manufacturer recommends avoiding breastfeeding during treatment and for 1 day after treatment.

### **Drug Levels**

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

#### **Effects in Breastfed Infants**

Relevant published information was not found as of the revision date.

#### **Effects on Lactation and Breastmilk**

Relevant published information was not found as of the revision date.

## **Alternate Drugs to Consider**

Eplerenone, Spironlactone

## **Substance Identification**

#### **Substance Name**

Finerenone

### **CAS Registry Number**

1050477-31-0

# **Drug Class**

**Breast Feeding** 

Lactation

Mineralocorticoid Receptor Antagonists